Rhumbline Advisers Exact Sciences Corp Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Exact Sciences Corp stock. As of the latest transaction made, Rhumbline Advisers holds 223,425 shares of EXAS stock, worth $12.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
223,425
Previous 222,311 0.5%
Holding current value
$12.8 Million
Previous $9.39 Million 61.98%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
BUY
$42.43 - $70.83 $47,267 - $78,904
1,114 Added 0.5%
223,425 $15.2 Million
Q2 2024

Aug 01, 2024
SELL
$41.33 - $74.26 $9,175 - $16,485
-222 Reduced 0.1%
222,311 $9.39 Million
Q1 2024

May 09, 2024
SELL
$56.27 - $73.77 $143,713 - $188,408
-2,554 Reduced 1.13%
222,533 $15.4 Million
Q4 2023

Feb 08, 2024
SELL
$59.06 - $75.72 $79,022 - $101,313
-1,338 Reduced 0.59%
225,087 $16.7 Million
Q3 2023

Nov 09, 2023
SELL
$65.94 - $99.04 $186,478 - $280,085
-2,828 Reduced 1.23%
226,425 $15.4 Million
Q2 2023

Aug 08, 2023
BUY
$62.68 - $95.05 $1.87 Million - $2.84 Million
29,859 Added 14.97%
229,253 $21.5 Million
Q1 2023

May 11, 2023
BUY
$47.19 - $70.77 $121,514 - $182,232
2,575 Added 1.31%
199,394 $13.5 Million
Q4 2022

Feb 14, 2023
BUY
$30.35 - $53.15 $320,010 - $560,413
10,544 Added 5.66%
196,819 $9.75 Million
Q3 2022

Nov 10, 2022
BUY
$31.97 - $49.37 $308,510 - $476,420
9,650 Added 5.46%
186,275 $6.05 Million
Q2 2022

Aug 11, 2022
BUY
$35.61 - $76.23 $550,103 - $1.18 Million
15,448 Added 9.58%
176,625 $6.96 Million
Q1 2022

May 12, 2022
SELL
$57.56 - $82.54 $349,389 - $501,017
-6,070 Reduced 3.63%
161,177 $11.3 Million
Q4 2021

Feb 10, 2022
BUY
$72.5 - $100.68 $274,485 - $381,174
3,786 Added 2.32%
167,247 $13 Million
Q3 2021

Nov 12, 2021
SELL
$90.24 - $124.05 $199,881 - $274,770
-2,215 Reduced 1.34%
163,461 $15.6 Million
Q2 2021

Aug 05, 2021
BUY
$93.66 - $139.27 $958,797 - $1.43 Million
10,237 Added 6.59%
165,676 $20.6 Million
Q1 2021

May 06, 2021
SELL
$116.57 - $155.01 $691,493 - $919,519
-5,932 Reduced 3.68%
155,439 $20.5 Million
Q4 2020

Feb 10, 2021
SELL
$99.61 - $142.12 $253,507 - $361,695
-2,545 Reduced 1.55%
161,371 $21.4 Million
Q3 2020

Nov 12, 2020
SELL
$72.92 - $102.01 $572,713 - $801,186
-7,854 Reduced 4.57%
163,916 $16.7 Million
Q2 2020

Aug 13, 2020
BUY
$55.75 - $92.75 $1.49 Million - $2.48 Million
26,714 Added 18.42%
171,770 $14.9 Million
Q1 2020

May 06, 2020
SELL
$37.9 - $104.44 $2,956 - $8,146
-78 Reduced 0.05%
145,056 $8.41 Million
Q4 2019

Feb 05, 2020
BUY
$77.66 - $99.74 $1.13 Million - $1.45 Million
14,570 Added 11.16%
145,134 $13.4 Million
Q3 2019

Oct 23, 2019
SELL
$90.37 - $122.49 $127,602 - $172,955
-1,412 Reduced 1.07%
130,564 $11.8 Million
Q2 2019

Aug 14, 2019
BUY
$89.51 - $118.04 $753,226 - $993,306
8,415 Added 6.81%
131,976 $15.6 Million
Q1 2019

May 01, 2019
BUY
$61.98 - $96.5 $16,858 - $26,248
272 Added 0.22%
123,561 $10.7 Million
Q4 2018

Jan 31, 2019
SELL
$56.04 - $82.66 $322,958 - $476,369
-5,763 Reduced 4.47%
123,289 $7.78 Million
Q3 2018

Nov 07, 2018
SELL
$48.29 - $80.6 $115,123 - $192,150
-2,384 Reduced 1.81%
129,052 $10.2 Million
Q2 2018

Aug 06, 2018
BUY
$37.84 - $69.96 $566,540 - $1.05 Million
14,972 Added 12.86%
131,436 $7.86 Million
Q1 2018

May 02, 2018
SELL
$39.82 - $57.53 $214,550 - $309,971
-5,388 Reduced 4.42%
116,464 $4.7 Million
Q4 2017

Feb 09, 2018
SELL
$46.49 - $60.51 $888,656 - $1.16 Million
-19,115 Reduced 13.56%
121,852 $6.4 Million
Q3 2017

Nov 06, 2017
BUY
$37.05 - $47.12 $5.22 Million - $6.64 Million
140,967
140,967 $6.64 Million

Others Institutions Holding EXAS

# of Institutions
673
Shares Held
162M
Call Options Held
2.58M
Put Options Held
2.19M
View Full List

About EXACT SCIENCES CORP

EXAS Quotes by TradingView
  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.2B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email